RT Journal Article
SR Electronic
T1 Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.05.23299397
DO 10.1101/2023.12.05.23299397
A1 Schmaderer, Theresa M.
A1 Towns, Clodagh
A1 Jasaityte, Simona
A1 Tan, Manuela M. X.
A1 Pollard, Miriam
A1 Hodgson, Megan
A1 Wu, Lesley
A1 Tilney, Russel
A1 Labrum, Robyn
A1 Hehir, Jason
A1 Polke, James
A1 Bhatia, Kailash P.
A1 Houlden, Henry
A1 Wood, Nicholas W.
A1 Jarman, Paul R.
A1 Morris, Huw R.
A1 Real, Raquel
A1 ,
YR 2023
UL http://medrxiv.org/content/early/2023/12/05/2023.12.05.23299397.abstract
AB The Parkinson’s Families Project is a UK-wide study aimed at identifying genetic variation associated with familial and early-onset Parkinson’s disease (PD). We recruited individuals with a clinical diagnosis of PD and age at motor symptom onset ≤ 45 years and/or a family history of PD. Where possible, we also recruited affected and unaffected relatives. We analysed DNA samples with a combination of single nucleotide polymorphism (SNP) array genotyping, multiplex ligation-dependent probe amplification (MLPA), and whole genome sequencing (WGS). We investigated the association between identified pathogenic mutations and demographic and clinical factors such as age at motor symptom onset, family history, motor symptoms (MDS-UPDRS) and cognitive performance (MoCA). We completed baseline genetic analysis in 714 families, of which 196 had sporadic early-onset PD (sEOPD), 112 had familial early-onset PD (fEOPD) and 406 had late-onset familial PD (fLOPD). 53 (7.4%) of these families carried known pathogenic variants causing PD. We identified pathogenic mutations in LRRK2 in 4.1% of families, and bi-allelic pathogenic mutations in PRKN in 2.4% of families. We also identified pathogenic mutations in two families with SNCA duplications, and single families with pathogenic mutations in VCP, PINK1, PNPLA6, PLA2G6 and SPG7. Most early-onset and familial PD cases do not have a known genetic cause, indicating that there are likely to be further monogenic causes for PD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Janet Owen’s bequest fund, the Walker-Peltz charitable fund, the Medical Research Council (MRC-G0700943), Cure Parkinson’s Trust, Parkinson’s UK (K-1501) and the National Institute for Health Research (NIHR) Clinical Research Network (CRN) North Thames.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The London Camden and Kings Cross Research Ethics Committee gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAnonymized datasets are available from the corresponding authors upon reasonable request.